JPMorgan Chase & Co. set a €71.00 ($78.89) target price on Sanofi SA (EPA:SAN) in a research note published on Thursday morning. The firm currently has a a sell rating on the stock.

Several other research firms also recently weighed in on SAN. BNP Paribas set a €78.00 ($86.67) target price on Sanofi SA and gave the company a neutral rating in a research report on Wednesday, September 14th. Jefferies Group set a €76.00 ($84.44) target price on Sanofi SA and gave the company a neutral rating in a research report on Tuesday, September 13th. Berenberg Bank set a €93.00 ($103.33) target price on Sanofi SA and gave the company a buy rating in a research report on Thursday, September 8th. Kepler Capital Markets set a €89.00 ($98.89) target price on Sanofi SA and gave the company a buy rating in a research report on Thursday, August 11th. Finally, Societe Generale set a €100.00 ($111.11) target price on Sanofi SA and gave the company a buy rating in a research report on Monday, August 1st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of €86.76 ($96.41).

Sanofi SA (EPA:SAN) opened at 69.63 on Thursday. The stock has a market capitalization of €89.61 billion and a PE ratio of 21.65. The stock has a 50 day moving average price of €25.99 and a 200-day moving average price of €25.72. Sanofi SA has a 12-month low of €22.81 and a 12-month high of €69.97.

About Sanofi SA

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with Analyst Ratings Network's FREE daily email newsletter.